Skip to main content

Ozempic News

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 – For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes,...

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 – Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease, according to a study...

Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes

FRIDAY, May 24, 2024 – Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug significantly reduces the...

Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds

THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...

Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans

WEDNESDAY, May 22, 2024 – The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report...

GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults

WEDNESDAY, May 22, 2024 – For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research letter published...

'Hungry Gut' Gene Test Shows Who'll Benefit Most From Wegovy

TUESDAY, May 21, 2024 – You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only...

Semaglutide Has Lasting Benefit for Weight Loss

TUESDAY, May 21, 2024 – Semaglutide has a long-term beneficial impact on weight, as well as cardiovascular benefits, regardless of weight loss, according to two studies presented at the annual...

Stomach Paralysis Risk May Rise in People Taking Ozempic and Similar Drugs

MONDAY, May 20, 2024 – New, real-world research confirms that the blockbuster weight-loss drugs that millions of Americans have been taking to shed pounds can trigger stomach paralysis in some...

Semaglutide Reduces Need for Diuretics in Heart Failure

THURSDAY, May 16, 2024 – Semaglutide reduces the need for loop diuretics and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved...

Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist

TUESDAY, May 14, 2024 – One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to...

GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription

WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...

More Studies Support Wegovy's Long-Term Weight-Loss Benefits

TUESDAY, May 14, 2024 – Semaglutide – the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy – can produce long-term weight and heart health benefits, a pair of new studies...

One in 8 U.S. Adults Have Now Used Blockbuster Meds Like Ozempic

FRIDAY, May 10, 2024 – About 1 in 8 U.S. adults (12%) have tried a weight-loss drug like Wegovy, Ozempic, Zepbound or Mounjaro, a new KFF Health Tracking Poll says. About 6% are taking one right...

Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV

TUESDAY, April 30, 2024 – For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Cardiovascular Risk Reduction, Diabetes, Type 2

Ozempic patient information at Drugs.com